GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Autolus Therapeutics PLC (NAS:AUTL) » Definitions » Institutional Ownership

Autolus Therapeutics (Autolus Therapeutics) Institutional Ownership : 13.57% (As of May. 23, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Autolus Therapeutics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Autolus Therapeutics's institutional ownership is 13.57%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Autolus Therapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Autolus Therapeutics's Float Percentage Of Total Shares Outstanding is 74.06%.


Autolus Therapeutics Institutional Ownership Historical Data

The historical data trend for Autolus Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Autolus Therapeutics Institutional Ownership Chart

Autolus Therapeutics Historical Data

The historical data trend for Autolus Therapeutics can be seen below:

2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30
Institutional Ownership 2.52 2.59 2.43 2.39 2.84 5.10 4.79 9.43 13.56 13.57

Autolus Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Autolus Therapeutics (Autolus Therapeutics) Business Description

Traded in Other Exchanges
Address
191 Wood Lane, The MediaWorks, London, GBR, W12 7FP
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.

Autolus Therapeutics (Autolus Therapeutics) Headlines

From GuruFocus

Autolus Therapeutics announces Board changes

By Stock market mentor Stock market mentor 01-20-2023